Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, international, real world cohort study of obeticholic acid in patients with primary biliary cholangitis

Trial Profile

A multicenter, international, real world cohort study of obeticholic acid in patients with primary biliary cholangitis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2023 Results assessing safety and effectiveness of obeticholic acid treatment on biochemical and liver function scores, GLOBE-PBC and UK-PBC at 5 yearspresented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 02 Aug 2023 According to an Intercept Pharmaceuticals media release, Intercept remains on track for a planned regulatory submission to the FDA in 2023 in support of fulfilling post-marketing requirements for Ocaliva in PBC. This submission will include data from this study.
    • 12 Dec 2020 Results (n=120) published in the Alimentary Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top